Avanti Polar Lipids, Inc.   Report issue

For profit Phase 2
Founded: Alabaster AL United States (1969)
Status: No NME R&D (1969)

Organization Overview

First Clinical Trial
2007
NCT00406536
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Hepasome Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 2)

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4